3-MeO-PCE
 | |
| Systematic (IUPAC) name | |
|---|---|
|
N-ethyl-1-(3-methoxyphenyl)cyclohexanamine | |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number | 1364933-80-1 |
| PubChem | CID 57461569 |
| ChemSpider | 27523972 |
| Chemical data | |
| Formula | C15H23NO |
| Molar mass | 233.36 g·mol−1 |
| |
| |
3-Methoxyeticyclidine (3-MeO-PCE) is a dissociative anesthetic drug that has been sold online as a designer drug.[1] The activity of 3-MeO-PCE in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCE was qualitatively similar to PCP.[2]
On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of Methoxetamine should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCE.[3]
This report also described the receptor binding profile of Methoxetamine and three additional dissociatives 3-MeO-PCP, 4-MeO-PCP and 3-MeO-PCE, showing them to have significant affinity for the PCP site of NMDAR and was later published in more detail.[4]
3-MeO-PCE has a Ki of 61 nM for the NMDA receptor, 115 nM for the serotonin transporter, 4519 nM for the sigma1 receptor and 525 nM for the sigma2 receptor.[4]
See also
References
- ↑ Giorgia De Paoli, Simon D. Brandt, Jason Wallach, Roland P. Archer, Derrick J. Pounder (April 2013). "From the Street to the Laboratory: Analytical Profiles of Methoxetamine, 3-Methoxyeticyclidine and 3-Methoxyphencyclidine and their Determination in Three Biological Matrices". Journal of Analytical Toxicology 37 (5): 277–283. doi:10.1093/jat/bkt023. PMID 23552616.
- ↑ Morris, H.; Wallach, J. (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis 6: 614–632. doi:10.1002/dta.1620. PMID 24678061.
- ↑ "(ACMD) Methoxetamine Report (2012)" (PDF). UK Home Office. 2012-10-18. p. 14. Retrieved 2015-06-17.
- 1 2 Bryan L. Roth, Simon Gibbons, Warunya Arunotayanun, Xi-Ping Huang, Vincent Setola, Ric Treble, Les Iversen (March 2013). "The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor". PLoS ONE 8 (3): e59334. doi:10.1371/journal.pone.0059334. PMID 23527166.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||
This article is issued from Wikipedia - version of the Friday, December 25, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.